At a glance
- Originator University of Texas at Austin
- Class Anthraquinones; Antineoplastics
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Nov 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 30 Jan 1998 Preclinical development for Cancer in USA (Unknown route)